Press coverage about Sienna Biopharmaceuticals (NASDAQ:SNNA) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sienna Biopharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.5945003731169 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Sienna Biopharmaceuticals traded down $0.11, reaching $15.80, during trading on Tuesday, MarketBeat reports. The company’s stock had a trading volume of 68,200 shares, compared to its average volume of 87,698. The stock has a market capitalization of $350.37 million and a price-to-earnings ratio of -3.04. Sienna Biopharmaceuticals has a 1-year low of $13.37 and a 1-year high of $29.25.
Get Sienna Biopharmaceuticals alerts:Sienna Biopharmaceuticals (NASDAQ:SNNA) last posted its quarterly earnings data on Monday, May 14th. The company reported ($0.85) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.70) by ($0.15). equities research analysts forecast that Sienna Biopharmaceuticals will post -2.91 EPS for the current year.
A number of analysts have recently weighed in on the company. ValuEngine raised Sienna Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research raised Sienna Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 31st. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $32.25.
In other news, insider Todd Harris sold 18,011 shares of the firm’s stock in a transaction on Wednesday, April 18th. The stock was sold at an average price of $20.08, for a total value of $361,660.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 19,086 shares of company stock valued at $383,161 in the last three months. Insiders own 27.00% of the company’s stock.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Read More: How Short Selling Works
No comments:
Post a Comment